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NF-E2 related factor-2 (NRF2) is an essential transcription factor for multiple genes encoding antioxidants and detoxification
enzymes. NRF2 is implicated in promoting cancer therapeutic resistance by its detoxification function and crosstalk with
proproliferative pathways. However, the exact mechanism of this intricate connectivity between NRF2 and growth factor
induced proliferative pathway remains elusive. Here, we have demonstrated that pharmacological activation of NRF2 by tert-
butylhydroquinone (tBHQ) upregulates theHER family receptors, HER2 andHER3 expression, elevates pAKT levels, and enhances
the proliferation of ovarian cancer cells. Preactivation of NRF2 also attenuates the combined growth inhibitory effects of HER2
targeting monoclonal antibodies, Pertuzumab and Trastuzumab. Further, tBHQ caused transcriptional induction of HER2 and
HER3, while SiRNA-mediated knockdown of NRF2 prevented this and further caused transcriptional repression and enhanced
cytotoxicity of the HER2 inhibitors. Hence, NRF2 regulates both HER2 and HER3 receptors to influence cellular responses to
HER2 targeting monoclonal antibodies. This deciphered crosstalk mechanism reinforces the role of NRF2 in drug resistance and
as a relevant anticancer target.
1. Introduction
The receptor tyrosine kinases (RTKs) are key drivers of nor-
mal cellular proliferation, differentiation, and survival, as well
as determinants of cancer initiation, maintenance, and pro-
gression [1–4]. Dimerization and stimulation of the intrinsic
tyrosine kinase in RTKs lead to the phosphorylation of
tyrosine residues in the intracellular domain of the receptors.
The phosphotyrosine residues serve as docking sites to recruit
a number of signal adapter proteins containing the so-called
SH2 and PTB domains, which link RTKs to different cellular
signaling pathways such as PI3K/AKT/mTOR, MAPK, and
STAT pathways [5, 6]. Among the RTK superfamily receptors
are the type I RTKs that belong to the epidermal growth
factor receptor (EGFR or HER) family. The HER receptor
network contains four members (HER1, HER2, HER3, and
HER4) whose activation kinetics depend significantly on
their expression levels which vary across different cells and
cancers [7]. Likewise it is these variations combined with
receptor interaction that drive and confer complexity in the
HER receptor family behaviour.
The two receptors, HER2 and HER3, are nonautonomous
and possess certain defining features, in that HER2 has
autokinase activity but no known ligands, and HER3 is a
pseudokinase receptor that lacks tyrosine kinase activity.
These features define the interaction between the HER2 and
HER3 receptors and for forming active homodimer and
heterodimer complexes. Specifically, mutation or increased
gene copy number leads to overexpression of HER2 receptors
in cancer cells causing constitutive activation of proliferative
pathways in the absence of ligand through homodimer-
ization and RTK autophosphorylation [1, 5, 6, 10]. HER2
functions as the shared coreceptor for EGFR, HER3, and
HER4 receptors, and these heterodimeric complexes are
activated by the partner ligands [11, 12]. Moreover, HER2
is the preferred heterodimerization partner of HER3, whilst
HER2 overexpression is believed to enhance the signaling
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from HER3 receptor in response to binding of its specific
ligand, neuregulin. As such, HER2-HER3 heterodimers are
known to be the strongest elicitors of the PI3K/AKT/mTOR
pathway [13–17]. Coexpression of the different receptors, the
diversity in their ligand-independent and ligand-dependent
activation, variation in their preference towards dimerization
partners, and receptor-dependent specificity in cells play
a major role in both redundancy in the HER network
interaction and effective drug target identification [17–21].
Further complexity in HER2/HER3 activation and signaling
arises from the complex transcriptional and posttranslational
coregulation of HER2/HER3 receptors and their ligands
following HER receptor specific targeted therapies which
often lead to inconsistent tumour responses [13, 17, 21].
Nuclear factor- (erythroid-derived 2-) like 2 (NRF2) is a
leucine zipper transcription factor and themaster regulator of
the antioxidant response (AR) pathway. It drives both basal
and oxidative stress-induced transcription of a battery of
phases I, II, and III detoxification enzymes and cytoprotective
genes [22–24] as well as other genes of the metabolic and
signal transduction pathways [14, 23, 25]. This is achieved by
heterodimerization of NRF2 with small MAF proteins and
binding to some genome cis-acting factors called antioxidant
response elements (ARE) or electrophile response elements
(EpREs) within the promoters of its target genes [26, 27].
Under basal conditions, only a low level of free NRF2 is
available in the cytoplasm with some translocating into the
nucleus to drive the basal transcription of target genes.
Like the HER receptors [28–31], NRF2 is a recognised
agent in cellular proliferation and adaptation to reactive
oxygen species (ROS) and in conferring therapeutic resis-
tance to cancers [32–34]. Importantly, NRF2 activation
and KEAP1 inactivation mutations leading to permanent
constitutive adaptive activation of the NRF2 pathway are
frequently observed in cancers [35–37]. Also several thera-
peutic strategies such as anticancer radio- and chemotherapy
greatly depend on ROS manipulation to induce cytotoxicity.
Paradoxically, there is a growing body of evidence implicating
HER2/HER3, NRF2, and ROS in the promotion of cellular
proliferation and therapeutic resistance in cancer cells [38,
39]. Cancer cells have been shown to evolve intricate mecha-
nisms of cellular resistance towards bothROS andother cellu-
lar damaging agents as demonstrated by a very robust antiox-
idant sensing and ROS neutralising mechanisms as well as a
highly efficient cytoprotective systems [33, 34, 40–42].
ROS is long not only recognised as the regulator of NRF2
stability and activity but has also been shown to trigger both
the AR and theHER family receptor pathways with concomi-
tant transcriptional upregulation of HER2/HER3 complexes
and subsequent activation of their functions [30, 31, 43, 44].
Hence, ROS might serve as the point of convergence and as
such establish cross relationship between the two pathways.
Furthermore, components of the receptor regulated PI3K and
MAPK have been shown to regulate NRF2 function [45–
47], while many aspects of RTK signaling are regulated by
ROS whose levels are directly modulated by NRF2 function
[48, 49].
Since NRF2 is a transcription factor to several hun-
dreds of genes, including proto-oncogenes, it is feasible that
HER2/HER3 receptors are transcriptional targets of NRF2
via direct or indirect means involving ROS. Thus this study
aims to investigate this and identify crosstalk between the
NRF2 dependent AR pathway and theHER2/HER3 receptors
signaling pathway, in order to determine their potential inter-
dependence in eliciting cellular proliferation, cytoprotection,
and responses to therapies.
By generating gene transcriptional reporter assays, car-
rying out pharmacological activation or SiRNA knockdown
of NRF2, and performing HER2/HER3 functional inhibi-
tion and activation strategies, we have identified a direct
node of functional integration of the two pathways in our
ovarian cancer cell model which converges at NRF2. We
demonstrated that inhibition of NRF2 leads to disruption
of the antioxidant pathway and attenuation of HER2/HER3
signaling and that this is as a consequence of transcriptional
repression of both HER2 and HER3 genes. Furthermore, we
have demonstrated that this functional link could be utilised
to either sensitise or reproduce resistant responses in our
cell model. Thus, this study reveals a new mechanism of
crosstalk between AR and HER2/HER3 pathways and opens
up novel avenues of targeting and manipulating the NRF2-
AR to uncouple and sensitise HER2/HER3 pathways resistant
ovarian cancer cells to targeted immunotherapeutics.
2. Materials and Methods
2.1. Cell Lines, Culture Conditions, and Treatments. Human
ovarian cancer cell lines PEO1 and SKOV3 were maintained
in RPMI 1640 media (Gibco Invitrogen) supplemented with
10% foetal bovine serum (FBS), 2mM glutamine, 1mM
sodium pyruvate, 100 𝜇g/mL streptomycin, and 100U/mL
penicillin in an atmosphere of 5%CO
2
and incubated at 37∘C.
Before experimental treatments, cells were grown for 24 h
in RPMI 1640 media prepared as above but replacing FBS
with 5% double charcoal stripped FBS (Fisher). Heregulin-𝛽1
(HRG, Sigma) was used by preparing 1𝜇mol/L stock solution
made with 5% trehalose and 10% FBS in phosphate buffered
saline (PBS) and diluted to a final concentration of 1 nmol/L
with media during treatments. Monoclonal antibodies tar-
getingHER2 receptor, Pertuzumab and Trastuzumab (RTKi),
were used by directly diluting the drugs in media to a final
concentration of 20𝜇g/mL. Tert-butylhydroquinone (tBHQ)
stock solution (Sigma) was made with Dimethylsulfoxide
(Fisher) and diluted to a final concentration as required with
media. For ROS detection, 2󸀠,7󸀠-Dichlorofluorescin diacetate
(DCFDA, Sigma) solution was prepared with Dimethylsul-
foxide in amber tubes to a concentration of 50mM and
stored at −20∘C in the dark until used. For cytotoxicity
assay, 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide (MTT) was needed by making a stock solution of
5mg/mL in PBS and filter sterilising it. The solution was
stored at 4∘C in the dark until used.
2.2. Reactive Oxygen Species (ROS) Detection. ROS detection
assay was performed by using 2󸀠,7󸀠-Dichlorofluorescin diac-
etate (DCFDA) staining (Sigma). Briefly, cells were seeded
in triplicate at a density of 0.2 × 105 cells/well of opaque
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flat bottom 96-well tissue culture plates in 100𝜇L media
without phenol red and allowed to grow for 18 h. Following
transfection, cells were washed with PBS and maintained
in 100 𝜇L of phenol red-free medium and further incubated
for 24 h. A 50mM stock solution of DCFDA was added to
each well containing 100 𝜇L preexisting media to achieve a
final concentration of 25𝜇M and incubated for 45min at
37∘C. Fluorescence signal intensities indicating ROS levels
were recorded by taking readings using 96-well fluorescent
multiplate reader (MODULUS, Promega) using excitation
and emission spectra of 485 nm/535 nm. To normalise the
fluorescence signal, cells in the same wells were stained with
Coomassie brilliant blue stain (Sigma) for 1 h and washed
with distilled water and 10% sodium dodecyl sulphate (SDS)
solution was added to release the absorbed dye for 10min
while shaking. The absorbance values at 595 nm were then
recorded using a multiplate absorbance reader (MODULUS,
Promega) data used after normalising the fluorescence values.
2.3. Cloning and Expression Vectors Used in the Study.
Closely 1.5 kb proximal promoter regions of HER2 and
HER3 were cloned and used in the current study. The
HER2 primer sequences used for each construct were HER2
forward: 5󸀠-GTGCTCGAGGCAAGAAGGGTGCATTTT-
GAAG-3󸀠 and HER2 reverse: 5󸀠-GTCAAGCTTGTCTCT-
TGGATGGGCCATC-3󸀠. The HER3 primer sequences used
for each construct were HER3 forward: 5󸀠-GTGCTCGAG-
GCCCTCTAGGTTGCATATCAATAGG-3󸀠 and for HER3
reverse: 5󸀠-GTCAAGCTTGAAAAGCAAGCCCAGCAC-
3󸀠. For cloning HER2 and HER3 promoters (prHER2 and
prHER3, resp.), total genomicDNAwas isolated fromhuman
cells using DNeasy Blood and Tissue Kit (Qiagen) and
quantified usingAstraGenemicrovolume spectrophotometer
(AstraNet). 100 ng of the genomic DNA was used to amplify
the promoter sequences (MyFi mix, Bioline) using relevant
primers that incorporated XhoI and HindIII restriction
endonuclease sites 5󸀠 and 3󸀠 ends of the amplified promoters,
respectively. PCR conditions for promoter amplification were
initial denaturation of 95∘C for 7min followed by 35 cycles of
95∘C for 30 s for denaturation, 50∘C for 30 s for annealing,
and 72∘C for 90 s for extension and a final extension for
10min at 72∘C. The PCR products were run and extracted
from agarose gel (Qiagen), digested using XhoI and HindIII
restriction enzymes (Promega), and ligated into PGL3 vector
(Promega) to created HER2 and HER2 promoter constructs
(prHER2 and prHER3, resp.) driving the expression of
luciferase gene for utilisation in dual luciferase reporter assay
(Promega).The integrity of cloned sequenceswas determined
by sequencing the plasmids using commercial sequencing
service (http://www.dnaseq.co.uk/). All cloned constructs
were transfected into relevant cell lines using Lipofectamine
3000 (Life Technologies).
2.4. Protein Extraction and Immunoblotting. For immunob-
lotting, cells were seeded in 60mm tissue culture plates and
grown until being 70% confluent. At the time of protein
harvest, cells were trypsinized (Gibco Invitrogen) andwashed
with PBS. Protein lysates were prepared using radio immune
precipitation assay buffer (Pierce Biotech) supplemented
with protease and phosphatase inhibitor cocktail (Pierce
Biotech) and subjected to sonication of 2 cycles for 10 s at
50% pulse. The final mixture was shaken gently on ice for
15min and the protein supernatant was obtained following
centrifugation of the lysates at 14000 g for 15min. Proteins
obtained were quantified by Bradford assay (Sigma-Aldrich)
using bovine serum albumin as a standard and sample buffer
(Nupage LDS, Invitrogen) was added to protein lysates,
heated at 70∘C for 20min, and stored at −20∘C until further
use. Once the protein lysates were prepared, they were
loaded into wells of 4–12% gradient SDS-polyacrylamide gels
(Nupage Bis-Tris gels, Life Technologies) and subjected to
electrophoresis at 200V for 1-2 h. Following this, proteins
were transferred to polyvinylidene difluoride membranes
(PVDF, GE Amersham) using the XCell SureLock Mini-Cell
system (Invitrogen) at 50V for 90min and processed using
a commercially available kit (WesternBreeze Chromogenic
Immunodetection Kit, Invitrogen). Nonspecific reactivity
was blocked by incubationwith the blocking reagent supplied
in the kit. Membranes were further treated by incubating
with primary antibodies (Table 1) for 2 h at room temperature
or overnight at 4∘C, followed by incubation for 30min at
room temperature with appropriate secondary anti-rabbit
antibody supplied in the kit. Bandswere visualizedwith the 5-
Bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium
chloride based chromogenic substrate. For loading control,
immunoblotting of the same lysates was performed using
either Beta-actin (𝛽-actin) antibody (AbcamBioscience, UK)
or the PVDFmembranes with transferred proteins visualised
using Ponceau stain (Sigma).
2.5. Luciferase Reporter Assay. For the analysis of promoter
activities and transcriptional regulation, the 1.5 kb promoter
regions of HER2 and HER3 genes cloned in pGL3 basic
vector (Promega) were transfected into relevant cell lines.
Briefly, cells were seeded in triplicate in 24-well plates at a
density of 2 × 105 cells per well and allowed to attach for
18 h. Following this, cells were transfected with either 1𝜇g
of empty pGL3 basic vector (Promega) or pGL3 basic vector
with cloned fragments of HER2 or HER3 promoters driving
the expression of luciferase gene, using Lipofectamine 3000 as
transfection reagent according tomanufacturer’s instructions
(Life Technologies). Cotransfection was also performed with
0.2 𝜇g of pRL-CMV vector (Promega) to provide for an
internal control of transfection. Following this, cells were
allowed to grow for 24 h, subjected to desired treatments
and lysed and protein lysates transferred to opaque white
bottom 96-well plates. The dual luciferase activity of fire
fly luciferase (from cloned promoters) and Renilla (internal
control) in the harvested lysates was measured sequentially
by following manufacturer’s instructions (Promega) and
taking luminescence readings in luminometer (MODULUS,
Promega). To determine the transcriptional activity of NRF2
in PEO1 and SKOV3 cell lines, basic pGL3 vector (Promega)
containing cloned 8 x cis regulatory ARE promoter elements
was transfected into the cell lines grown in 24-well plates
and subjected to dual luciferase reporter assay (Promega) as
described above.
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Table 1: Antibodies used in the study.
Antibody Host Catalogue number Company
NRF2 Rabbit Sc-722 Santa Cruz
Phospho-NRF2 S-15 Rabbit ab76026 Abcam
HER2 Rabbit 2165S Cell Signalling
HER3 Rabbit 4754S Cell Signalling
Phospho-HER2 T877 Rabbit 2241S Cell Signalling
Phospho-AKT 473 Rabbit 4060S Cell Signalling
BID Rabbit 2002 Cell Signalling
Phospho-ERK p44/p22 Rabbit 4379 Cell Signalling
Heme oxygenase-1 (HO-1) Rabbit Sc-10789 Santa Cruz
Alexa Fluor 488 conjugated secondary antibody Rabbit ab150077 Abcam
Alexa Fluor 568 conjugated secondary antibody Rabbit ab175471 Abcam
2.6. SiRNA Transfection. Small inhibitory RNA (SiRNA)
was used to knockdown NRF2 (Hs NFE2L2 6, Qiagen). For
SiRNA transfection, cells were seeded in triplicate either in
24-well plates (0.5 × 105 cells), in 60mm plates with cells
grown on poly-L lysine coated coverslips (0.5 × 106 cells),
or in 96-well plates in triplicate (2 × 104) and allowed to
grow for 24 h. Following this, cells were cotransfected using
either 20 pmol SiRNA and 1 𝜇g of different PGL3 promoter
constructs (24-well plate) or 75 pmol and 100 pmol SiRNA
only (60mm plates) or 7 pmol of SiRNA (96-well plate) and
incubated for a further 24 h. Cells transfected in 24-well plate
were further processed for dual luciferase assay and those in
60mm plates were harvested for immunoblotting or used for
imaging analysis while those in 96-well plates were processed
for cytotoxicity assay. In all cases, scrambled SiRNAwas used
as a control while transfection was performed using Lipofec-
tamine 3000 (Life Technologies) according to manufacturer’s
instructions.
2.7. Cytotoxicity Assay. For cytotoxicity (or cell viability)
assay, cells were seeded in triplicate at a density of 0.5 ×
104 cells in 96-well plate and allowed to attach for 18 h. On
the day of treatment, old media were removed and 80 𝜇L
of media containing relevant drugs was added and the plate
was incubated for the required period of time. On the day of
assay, 20𝜇L of the 5mg/mL MTT stock was added to each
well and plate was further incubated for 4 h. Following this,
the old media with MTT were removed, cells were gently
washed with prewarmed PBS, and 100 𝜇L of DMSO was
added to solubilise the internalised MTT by shaking over an
orbital shaker for 15min. Absorbance of the released dye was
measured and recorded usingmultiplate reader (MODULUS,
Promega) at 540 nm.
2.8. Immunocytochemistry/Immunolabelling. For immuno-
cytochemistry, exponentially growing cells were seeded at
a density of 5 × 104 cells in complete media onto poly-
L lysine (Sigma-Aldrich) coated cover slips placed in a
12-well tissue culture plates. Next day, following relevant
treatments, cells were washed three times with ice cold PBS
and fixed in 3.5% paraformaldehyde in a standard PBS at
room temperature for 30min. Following this, cells were
gently washed twice with 1mL of PBS, permeabilized with
0.3% Triton X-100 for 10min, and, following three washes
with PBS, blocked with a solution containing 1% goat serum,
1% bovine serum albumin, and 0.05% Triton X-100 in PBS
for 30min. Cells were then incubated with relevant primary
antibody (Table 1) diluted in blocking solution for 1 h, washed
three times with 0.1% Triton X-100/PBS for 5min, and then
incubated with Alexa Fluor 488 or 568 conjugated goat anti-
rabbit (Table 1) for 30min. After subsequent three washes
with the 0.1% Triton X-100 in PBS for 5min, cover slips
with cells were mounted on slide using 4󸀠,6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI) containingmounting
reagent (Life Technologies) and imaged under relevant filters
with a Leica DMiRe2 electronic microscope.
2.9. Statistical Analysis. All statistical analyses were per-
formed using statistical software SPSS (IBM, version 22). Test
for normality of data was determined by Shapiro-Wilk and
Kolmogorov and Smirnov tests. The significance (𝑝 value)
of differences of pooled results was determined by either
independent 𝑡-tests or One WAY ANOVA followed by post
hoc Tukey’s tests. Significance was defined as ∗ = 𝑝 < 0.05,
∗∗ = 𝑝 < 0.01, and ∗ ∗ ∗ = 𝑝 < 0.001.
2.10. Imaging and Analysis. Quantitative analysis of raw
immunoblots was performed by capturing the images in high
resolution TIFF format files using a charge-coupled-device
camera (AxioCam MRc, Carl Zeiss) and subjected to Gelpro
analysis software, version 3.1 (Gelpro Media Cybernetics)
for integrated optimal densitometry. Fluorescence images of
immunocytochemistry were collected under relevant excita-
tion and emission filters depending on the fluorotype under
Leica DMiRe2 electronic microscope equipped with iXonEM
+897 EMCCD camera (ANDOR Technologies Ltd.). Images
were analysed using multidimensional microscopy software
Andor Module iQ Core. Colocalization assay was performed
and determined with software integral features supplied by
Andor iQ Core software. Data were generally expressed as
mean ± S.D. for individual sets of experiments.
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3. Results
3.1. Pharmacological Activation of NRF2 Enhances Ovarian
Cancer Cell Growth and Protects from Cytotoxicity Caused by
HER2-Targeted Immunotherapeutic Agents. Numerous stud-
ies have shown that NRF2 promotes resistance to chemother-
apeutic agents [50, 51] and contributes to general cyto-
protection, metabolic reprograming, and cell survival [52–
55]. On the other hand, targeted immunotherapy involving
inhibitory monoclonal antibodies against HER2 receptor has
generated interest in recent years as a potential strategy
to overcome ovarian cancer cell therapeutic resistance [17,
56]. Using HER2 overexpressing and low expressing ovarian
cancer cell lines SKOV3 and PEO1, respectively [57], we
first examined whether preactivation of NRF2 would change
the cytotoxic responses of these cells to HER2-targeted
immunotherapeutic agents Pertuzumab and Trastuzumab.
For this, cells were grown in media containing 5% charcoal
stripped FBS and 1 nmol/L Heregulin (HRG), a ligand for
the HER3 receptor [58] for relevant treatments. Firstly, we
found that pharmacological activation of NRF2 by tBHQ
alone was sufficient to enhance the proliferation of both
cell lines for six days (Figure 1). On the other hand and as
expected, exposure of cells to HER2 inhibitors, Pertuzumab
and Trastuzumab, inhibited the proliferation of both cell lines
for up to 4 days of treatment, while losing its inhibitory
effect on day 6. Interestingly, pretreatment of cells with
200𝜇M tBHQ for 5 h before the introduction of the HER2
inhibitors significantly protected cells from the inhibitory
action of the subsequently addedHER2 targetingmonoclonal
antibodies. This was consistent for both cell lines and for all
the treatment days tested (Figure 1). Furthermore, inclusion
of tBHQ with the inhibitors not only protected the cells
but increased survival even beyond the untreated levels on
days 2, 4, and 6 in PEO1 and days 1, 2, and 6 in SKOV3
cell lines (Figure 1). This demonstrated that NRF2 activation
is not only implicated in resistance to genotoxic agents as
previously demonstrated [55] but can also lead to resistance
to immunotherapies involving Pertuzumab and Trastuzumab
whose actions otherwise are very specific to HER2 receptors
and unrelated to antioxidant pathway.
3.2. TBHQ Treatment Causes Protein Induction of HER2 and
HER3 and Parallel Increase in Phospho-AKT S473. Previous
studies have examined the crosstalk between growth pro-
moting MAPK and PI3K pathways and NRF2 antioxidant
pathway in numerous cell systems. However, in the majority
of such studies, the focus was regulation of NRF2 by these
kinases [46, 47, 59, 60]. The observation that preactivation
of NRF2 led to resistance against agents of targeted therapy
(Figure 1) suggested potential regulation of HER2 dependent
growth pathways byNRF2.Hence, we next exposedPEO1 and
SKOV3 cell lines to a single concentration of tBHQ for 4 h
and examined the effects of such treatment on the protein
levels of HER2 and HER3 and their downstream substrate
pAKT Ser 473. Firstly, higher levels of HER2 receptor were
confirmed in SKOV3 cell line that was also accompanied by
induced basal pAKT, consistent with previous reports [61].
Secondly, following tBHQ treatment, we saw induction of
total HER2 and parallel consequential induction of pATK
levels in both cell lines. Further, HER3 was found to decrease
in PEO1 while being induced in SKOV3, demonstrating a
differential regulation of the receptors in the two cell lines
(Figures 2(a) and 2(b)). This is consistent with the increased
proliferation seen following tBHQ treatment, as an enhanced
cell surface expression of receptors would lead to a greater
degree of binding to their HRG ligand and triggers growth
promoting signaling.
To explore further HER2 and pAKT induction by tBHQ
at a single cell level, we performed subcellular localisation
by fluorescent double immunolabelling of these proteins in
PEO1 and SKOV3 cell lines following the same treatments
(Figure 2(c)). Consistent with Figure 2(a), we saw higher
expression ofHER2 in SKOV3 as compared to PEO1. For both
cell lines, pAKTwas found uniformly distributed in the cyto-
plasm and nucleus.This could be indicating the constitutively
active nature of this pathway and could be explained by the
presence ofHRG in themedia. Following tBHQ treatment for
4 h, we saw an increase in HER2 expression and an accompa-
nying increase in pAKT levels as well. Superimposition and
colocalisation of the images captured in the red and green flu-
orescence channels to indicate HER2 and pAKT, respectively,
were performed and showed increased localisation of the two
proteins, as demonstrated by the appearance of yellow fluo-
rescence following tBHQ as compared to untreated controls
(Figure 2(c)). To confirm and measure the enhanced colo-
calisation following treatments, we also performed further
imaging analysis by generating cytofluorograms and found
that Pearson’s coefficient of correlation (𝑟) increased in both
cell lines following tBHQ exposure (Figure 2(d)). Altogether,
these data illustrated effects of tBHQ treatment on RTK
mediated growth signaling.This was demonstrated by induc-
tion of HER2 and HER3 and activation of AKT following
pharmacological activation of NRF2, which supported the
enhanced proliferation seen before (Figure 1).
3.3. Pharmacological Activation of NRF2 Causes Transcrip-
tional Induction of HER2 and HER3 Genes. Previous studies
have shown transcriptional perturbation of HER2 and HER3
following different targeted therapy treatments [17]. In some
contexts, this was proposed to be used as a biomarker
for treatment response [61]. After finding the modulatory
effects of tBHQ treatment on protein levels of HER2 and
HER3 receptors, we next wanted to identify the mechanism
of this upregulation. Specifically, we wanted to examine
whether the protein inductions seen in Figure 2 result from
transcriptional regulation. To determine this, we generated
transcriptional reporter assays for both HER2 and HER3
receptors. This involved developing HER2 and HER3 pro-
moter driven luciferase reporter system (named prHER2
and prHER3, resp.). We transfected these luciferase reporter
systems carrying 1.5 kb of the upstream promoter regions of
the two receptors into both PEO1 and SKOV3 cell lines to
first determine their basal level of transcription and then
studied the effects of tBHQ treatment. Figure 3(a) interest-
ingly revealed that SKOV3 cell line exhibited enhanced basal
transcription of both HER2 and HER3 genes as compared to
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Figure 1: NRF2 activation causes cytoprotection from HER2-targeted agents, Pertuzumab and Trastuzumab. PE01 or SKOV3 cells in the
presence of 1 nM HRG were either left untreated (H) or treated with 20𝜇g/mL of HER2 inhibitors Pertuzumab and Trastuzumab (H + I),
200 𝜇M tBHQ (H + T), or combination of inhibitors and tBHQ (H + T + I). TBHQ was added 5 h in advance. Cell number was assessed
indirectly by use of the MTT assay. Values shown are means ± S.D. of triplicates normalised to untreated controls expressed as 1. Statistical
significance was calculated between H + I, H + T, and H + T + I groups by ONE WAY ANOVA followed by Tukey’s post hoc test according
to the scale ∗: 𝑝 < 0.05, ∗∗: 𝑝 < 0.01, and ∗ ∗ ∗: 𝑝 < 0.001.
PEO1 cell line (Figure 3(a)). However, the previous western
blot analysis in Figure 2 showed higher basal levels of HER3
in PEO1 as compared to SKOV3 whereas HER2 levels were
consistently higher in SKOV3. This illustrated that the over-
expression of HER2 in SKOV3 cell line could be explained by
both gene amplification [62] and higher basal transcription.
We next exposed cells transfected with the prHER2
and prHER3 reporter assays to increasing concentrations of
tBHQ to further explore the nature of this transcriptional
regulation. Strikingly, both PEO1 and SKOV3 cell lines
exhibited significant dose-dependent transcriptional induc-
tion of HER2 (Figure 3(b), blue bars). Interestingly, prHER3
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Figure 2: Continued.
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Figure 2: TBHQ treatment causes protein induction of HER2 and HER3 and upregulation of pAKT levels in PEO1 and SKOV3 cells. (a)
Immunoblot analysis following treatment with tBHQ demonstrated protein induction of both HER2 and HER3 receptors and increase of
pAKT. Exponentially growing cells were either left untreated (UT) or treated with 200 𝜇M tBHQ for 4 h before being harvested and processed
for immunoblotting using relevant antibodies (Table 1). (b) Bar chart showing total HER2, total HER3, and phospho-AKT levels in PEO1 and
SKOV3 cell lines by quantifying immunoblot signal intensities obtained in (a) and normalised to the value of UT and expressed as fold change.
(c) Immunofluorescent labelling of endogenous HER2 and phospho-AKT reveals protein induction following tBHQ treatment. Cells were
processed for immunocytochemistry and immunolabelled using anti HER2 (red fluorescence) or phospho-AKT (green fluorescence) primary
antibodies followed by Alexa Fluor conjugated secondary antibodies. Nuclear reference was provided by costaining with 4󸀠,6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI). Scale bar indicates 10𝜇m. (d) Analysis of colocalisation between immunostainedHER2 and pAKT in
the images obtained in (c). Spatial correlation between the twofluorescent signalswas obtained by generating cytofluorograms andperforming
Pearson’s correlation analysis.
exhibited a varying response. While prHER3 activity was sig-
nificantly induced in PEO1 following 50𝜇mtBHQ, increasing
dosage beyond 50𝜇M led to its repression. In SKOV3 cells
on the contrary, 50𝜇M tBHQ repressed prHER3 activity
while increasing dosage of 100 and 200𝜇M led to subsequent
induction (Figure 3(b), brown bars).This complex regulation
of HER3 is reminiscent of recent reports that revealed that
induction of HER2 might repress HER3 expression while its
inhibition could lead to transcriptional induction of HER3
[13, 14, 63]. This set of results confirmed the transcriptional
basis of induction of HER2 and HER3 protein levels, which
concomitantly also led to pAKT induction.
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Figure 3: Nrf2 activation leads to transcriptional induction ofHER2 andHER3 in a concentration dependentmanner. (a) SKOV3 cells exhibit
higher basal transcription of both HER2 and HER3. PEO1 and SKOV3 cells were transfected with either empty PGL3 basic vector or 1 𝜇g
PGL3 basic vector with cloned 1.5 kb fragments of either HER2 (prHER2) or HER3 (prHER3) promoter driving the expression of luciferase
gene. Cotransfection with 0.2 𝜇g pRL-CMV plasmid was performed as an internal transfection control. (b) TBHQ causes transcriptional
induction of HER2 and HER3 in a concentration dependent manner. PEO1 and SKOV3 cell lines were transfected in triplicate as in (a) but
were treatedwith different concentrations of tBHQas indicated for 4 h.Data shown are themeans± S.D. of triplicates, normalised to untreated
(UT) controls and expressed as fold change with statistical significance determined by ONEWAY ANOVA followed by Tukey’s post hoc test
(∗: 𝑝 < 0.05, ∗∗: 𝑝 < 0.01, and ∗ ∗ ∗: 𝑝 < 0.001).
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3.4. NRF2 Activation Desensitises RTK Signaling Pathway
to Combination of HER2 Targeting Monoclonal Antibodies
Pertuzumab and Trastuzumab. The observation that tBHQ
treatment led to transcriptional induction ofHER2 andHER3
suggests that NRF2 may be directly involved in regulating
the receptor expression and as such may influence responses
to targeted therapies involving HER2 inhibitors. This impor-
tant question was next investigated by treating PEO1 or
SKOV3 cells either with the combination of Pertuzumab and
Trastuzumab alone or by cotreatment with tBHQ to examine
the consequences of NRF2 activation on drug responses.
Interestingly, some features of the signaling response were
similar between these two cell lines while others were more
distinct. In the PEO1 cell line, treatment with inhibitors
alone induced both HER2 and HER3 levels consistent with
the parallel increase in phospho-HER2 T877 (Figure 4) in
this cell line. In contrast, for SKOV3, only HER3 expression
showed a minor induction while total HER2 levels were
reduced explaining the decrease in phospho-HER2 T877
levels as well. In order to better understand the effect of these
inhibitors on RTK signaling, we normalised the blot signal
of phospho-HER2 in both cell lines to the corresponding
values of total HER2 (Figure 4, blue bars). This analysis
interestingly revealed that while the inhibitors reduced the
ratio of phospho-HER2 to total HER2, cotreatment with
tBHQ restored the ratio back to that of untreated controls.
This effect was more pronounced in the SKOV3 cell line.
Importantly, in terms of pAKT S473, while 4 h treatment with
inhibitors led to minor repression of its levels as revealed by
the densitometry analysis, cotreatment with tBHQ protected
this repression and increased pAKT levels beyond that of
untreated controls (Figures 4(a) and 4(b)). These results
revealed that tBHQ can protect RTK signaling against the
inhibitory action of the drugs. We also included phospho-
ERK p44/p22 levels in our analysis as ERK was previously
shown to be inhibited by drugs targeting HER2 receptor
[56]. We saw a very minor repression of phospho-ERK levels
only in SKOV3 cells following 4 h of inhibitor treatment.
However, tBHQ dependent induction for ERK was seen in
PEO1 cells. Inhibitor treatment did not influence pNRF2 S15
levels in either of the cell lines, but as expected, its levels
increased following tBHQ treatment. Finally, we examined
intact and cleaved levels of proapoptotic protein BID in order
to further support our conclusions drawn from Figure 1.
By determining the ratio of cleaved BID over intact, we
observed that while treatment with inhibitors induced levels
of cleaved BID, tBHQ cotreatment led to a minor repres-
sion, further explaining the cytoprotective effect of tBHQ
treatment (Figure 4).These results revealed important conse-
quences of tBHQ treatment on targeted therapy using HER2-
targeted monoclonal antibodies and showed that treatment
with NRF2 activator attenuated the inhibitory action of these
monoclonal antibodies.
3.5. Knockdown of NRF2 by Small Inhibitory RNA (SiRNA)
Elevates ROS, Represses pNRF2 and Heme Oxygenase-1 (HO-
1) Levels, and Disrupts tBHQDependent Induction of ARE. In
order to confirm the direct role of NRF2 in tBHQ dependent
induction of HER2 and HER3 receptors, we next knocked
down NRF2 using SiRNA. To this end, we first optimized
and verified sufficient knockdown of NRF2 using specific
SiRNA and then studied the effects of this knockdown
on antioxidant pathway. As shown in Figure 5(a), 75 pmol
of NRF2 SiRNA produced maximum depletion of NRF2
both following 24 and 48 h of transfection, while 100 pmol
showed lesser depletion (Figure 5(a), black bars indicating
band intensities).We next determinedwhether this depletion
is sufficient to cause repression of the antioxidant pathway by
examining NRF2 substrates. We found that 75 pmol SiRNA
sufficiently downregulated phospho-NRF2 and HO-1 levels
as well (Figure 5(b)). Efficiency of internalisation of NRF2
targeting SiRNA in SKOV3 cells using different amounts was
confirmed and verified (Figure 5(c)).We next quantified total
basal ROS followingNRF2 knockdown to determinewhether
NRF2 depletion caused elevation of ROS. Loading of cells
with 2󸀠,7󸀠-Dichlorofluorescin diacetate dye which is a fluo-
rescent marker of intracellular ROS confirmed elevation of
ROS resulting from NRF2 knockdown (Figure 5(c)). Finally,
we performed immunostaining of endogenous pNRF2 and
HO-1 following transfection with either scrambled or NRF2
targeting SiRNA and as consistent with Figure 5(b), we
verified repression of pNRF2 and HO-1 levels at single cell
level (Figure 5(d)). Having confirmed the effectiveness of
our SiRNA-mediated NRF2 knockdown, we next examined
whether depletion of NRF2 would also disrupt tBHQ depen-
dent induction of antioxidant pathway in PEO1 and SKOV3
cell lines and thus confirm the direct involvement of NRF2 in
this mechanism. To do this, we exposed cells to tBHQ either
in the presence of endogenous NRF2 or following its genetic
depletion. Figure 6(a) revealed that NRF2 protein induction
seen in tBHQ treatment was disrupted following its SiRNA
transfection. Next, in order to confirm that NRF2 depletion
also caused inhibition of transcriptional antioxidant response
program and to further confirm the conclusions drawn from
Figure 5(b), we transfected cells with cis-antioxidant response
elements (ARE) in luciferase reporter vector driving the
expression of luciferase to report transcriptional activity of
NRF2. Firstly, we saw repression of ARE signal supporting
our conclusions drawn from Figure 5. Secondly, we saw
that the tBHQ treatment regime that had caused induction
of NRF2 protein levels (Figure 6(a)), and those of NRF2
substrate HO-1 (Figure 5(b)) and HER2 and HER3 receptor
expressions (Figures 2 and 3), also significantly enhanced the
activity of the NRF2 dependent antioxidant transcriptional
programme in both PEO1 and SKOV3 cell lines (Figure 6(b)).
Finally, we saw that such induction was inhibited following
knockdown of NRF2 to significant levels as compared to
tBHQ treatment alone. Altogether, Figures 5 and 6 provide
evidence of knockdown of NRF2, repression of the antiox-
idant response pathway, and disruption of tBHQ mediated
pathway induction.
3.6. NRF2 Depletion Causes Transcriptional Inhibition of
HER2 and HER3 Leading to Repression of HER2, HER3, and
pAKT Proteins and Sensitisation to Targeted Immunothera-
peutics. As shown in the previous sections, NRF2 activation
by tBHQ not only induced the NRF2 dependent antioxidant
response pathway as expected, but surprisingly also induced
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Figure 4: Continued.
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Figure 4: NRF2 activation desensitises RTK signaling pathway to HER2 inhibitors Pertuzumab and Trastuzumab. (a) Immunoblot analysis
showing tBHQ dependent recovery of RTK signaling following its inhibition by HER2 inhibitors. Exponentially growing cells were either left
untreated (UT) or treated with combination of HER2 inhibitors, Pertuzumab and Trastuzumab at concentration of 20𝜇g/mL (RTKi), or with
cotreatment of 200 𝜇M tBHQ (RTKi + T) for 4 h before and processed for immunoblotting using relevant antibodies (Table 1). Ponceau stain
of the same blot was used as loading control. (b) Bar chart showing total HER2, phospho-HER2, total HER3, phospho-AKT, phospho-ERK,
phospho-NRF2, and BID levels in PEO1 and SKOV3 cell lines by quantifying immunoblot signal intensities obtained in (a) and normalised
to the value of UT and expressed as fold change. Blue bars show ratio of phospho-HER2 to HER2 (upper panels) and cleaved BID to intact
BID (lower panels).
protein levels of HER2 and HER3 (Figure 2) and we further
confirmed that the protein upregulation was as a result
of their transcriptional induction (Figure 3). These findings
were important because such receptor induction attenuated
the inhibitory responses of HER2-targeted drugs (Figure 4).
As an alternative approach to study the regulation of HER
receptors by NRF2, we knocked down NRF2 in our cell
lines and firstly studied the protein levels of the receptors
and their downstream substrate, pATK.We found significant
protein repression of HER2 and HER3 as well as pAKT.
Quantification of the resulting immunoblot signals revealed
a greater repression with 75 pmol NRF2 SiRNA (Figure 7(a)).
Interestingly, we could also detect and capture such repres-
sion at single cell level by performing immunostaining for
HER2 and pAKT following either scrambled orNRF2 specific
SiRNA (Figure 7(b)). Immunolabelling also revealed localisa-
tional features of total HER2 and pAKT. HER2 was mostly
localised at the cell membrane as expected and apparently
without any nuclear staining. The pAKT on the other hand
was localised at the cell membrane, general cytosol and
nucleus, as revealed by immunostaining and the merger with
DAPI staining (Figure 7(b)). This is consistent with previous
reports of nucleocytoplasmic shuttling of pATK that could
have physiological consequences [63–65].
We next wanted to determine and confirm any tran-
scriptional mechanism of NRF2 specific SiRNA dependent
repression of HER2 and HER3. We thought this could be
a likely explanation as we earlier showed tBHQ dependent
transcriptional upregulation of HER receptors (Figure 3). To
address this, we again utilised our transcriptional reporter
assays for both HER2 and HER3 receptors that were estab-
lished for this study. Using our ovarian cell line models, we
individually transfected the reporter systems but, this time,
cotransfecting with NRF2 specific SiRNA as well. Following
this, cells were either left untreated or treated with tBHQ.We
found that following NRF2 knockdown, HER2 transcription
was significantly repressed in both PEO1 (Figure 7(c)) and
SKOV3 (Figure 7(d)) cell lines. In terms ofHER3,whileNRF2
knockdown significantly repressed transcription in SKOV3,
such repression was not seen in PEO1 (compare Figures
7(c) and 7(d) for prHER3). Interestingly, the tBHQ depen-
dent transcriptional induction of prHER2 and prHER3 gene
reporters as seen in Figure 4 was disrupted following deple-
tion ofNRF2 in both PEO1 and SKOV3 cell lines to significant
levels (Figures 7(c) and 7(d)). These important findings
confirmed that tBHQ mediated protein and transcriptional
induction of HER receptors was dependent on NRF2 and not
by any off NRF2 target effect of tBHQ treatment. Finally, we
repeated knockdown of NRF2 either alone or with parallel
knockdown of KEAP1 and exposed such cells to targeted
immunotherapeutics for 24 and 48 h (Figure 7(e)). We found
significant increase in cell death in NRF2 knockdown cells
upon exposure to the immunotherapeutics and significant
reversal of this response with parallel KEAP1 knockdown.
These results confirmed the transcriptional regulatory
role of NRF2 for HER2 and HER3 receptors and illus-
trated alteration of protein abundance as a result of
such transcriptional regulation. These data also confirmed
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Figure 5: Continued.
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Figure 5: Knockdown of NRF2 by SiRNA causes repression of phospho-NRF2 and HO-1 levels and elevation of reactive oxygen species
(ROS). (a) Optimization of SiRNA-mediated NRF2 knockdown. Exponentially growing cells were transfected either with scrambled RNA
(scrmbl) or with different amounts of SiRNA for either 24 h or 48 h before being processed for immunoblotting. (b) NRF2 knockdown results
in repression of its substrates. The same lysates as in (a) were blotted for phospho-NRF2 and HO-1 levels. Bar charts in (a) and (b) show total
NRF2, phospho-NRF2, and HO-1 levels in SKOV3 cell lines by quantifying immunoblot signal intensities obtained in respective blots and
normalised to the value of UT and expressed as fold change. (c) NRF2 knockdown leads to ROS accumulation. SKOV3 cells were seeded
in triplicate for 18 h and transfected with NRF2 SiRNA. Following 48 h incubation, cells were assayed for total ROS by loading them with
DCFDA for 45min and measuring fluorescence using fluorescence multiplate reader (MODULUS, Promega) with excitation and emission
spectra of 485 nm/535 nm. The fluorescence reading was normalised to total cell abundance within the same wells as described in Materials
andMethods. Data are the means with ±S.D. of triplicates, normalised to untreated (UT) control and expressed as fold change with statistical
significance determined by Student’s 𝑡-test according to the scale ∗: 𝑝 < 0.05, ∗∗: 𝑝 < 0.01, and ∗ ∗ ∗: 𝑝 < 0.001. (d) Immunofluorescent
labelling of endogenous phospho-NRF2 and HO-1 exhibits repression following NRF2 knockdown. Cells were transfected as in (a) and
processed for immunocytochemistry. Relevant primary antibodies followed by Alexa Fluor conjugated secondary antibodies were used for
immunolabelling for phospho-NRF2 and HO-1 (red fluorescence). Nuclear reference was provided by costaining with 4󸀠,6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI). Images were captured with Leica DMiRe2 electronic microscope with 100x objective while merging,
colocalisation, and further analysis were performed by using integrated features of Andor iQ Core software (ANDOR Technologies Ltd.).
Scale bar indicates 10 𝜇m.
the role of NRF2 in determining overall treatment responses
to HER2 targeting immunotherapeutics and hence defining
the balance between resistance and sensitivity.
4. Discussion
The receptor tyrosine kinases (RTKs), exemplified by HER2/
HER3 family receptors, are key regulators of cellular prolif-
eration, differentiation, and survival, as well as determinants
of cancer initiation, maintenance, and progression [1–4].
Complexity in understanding the HER2/HER3 activation
and signaling arises from the intricate and complex regu-
lation of coexpression of HER2/HER3 receptors and their
ligands and the broad spectrum of tumour biochemistry,
heterogeneity, and range of sensitivities and resistance exhib-
ited to drugs targeting the HER receptor system [13, 14, 17,
21]. Furthermore, clinical data on HER2/HER3 coexpression
profile correlates to some degree with disease-free survival,
not only regarding anti-RTK treatment outcome [66], but
also by other therapeutic agents [43, 67, 68]. However, it
has been suggested that sustained and complete inhibition
of HER3 and its output to PI3K/Akt is required for the
maximal antitumour effect of HER2 inhibitors [13, 16] and
that inhibition of HER2 receptor alone might not generate
sufficient anticancer response [16]. Lately, data have accrued
to evidence and implicate NRF2 and ROS, in addition to
HER2/HER3, in the promotion of cellular proliferation and
therapeutic resistance in cancer cells [31, 69, 70]. It is also
known that ROS can trigger both the AR and the HER
family receptor pathways with concomitant transcriptional
upregulation of HER2/HER3 and NRF2 and subsequent ele-
vation and activation of their functions [31, 68–70].Thus, the
HER2/HER3 family receptor signaling pathway is upstream
of PI3K/AKT/mTOR pathway [13–16] and has likewise been
shown to be upstream of theNRF-AR pathway as well [46, 47,
59, 60, 71, 72].These highlight the possibility of a more direct,
rather than indirect, contact and cross relationship between
the HER2/HER3 and NRF2-AR pathways. This crosstalk
could be likely and even necessary as RTK dependent growth
and metabolism creates ROS, which would require parallel
NRF2 dependent antioxidant pathway for its neutralisation.
Likewise, the implication of NRF2 in proliferative and cyto-
protective pathways may involve RTK dependent signaling
[73]. RTK-targeted cancer therapies are compromised or
limited when tumour cells circumvent the action of a single
agent, and multiple agents due to the readjustments in
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Figure 6: Knockdown of NRF2 by SiRNA represses both basal and induced antioxidant response pathway in PEO1 and SKOV3 cell lines. (a)
Immunoblotting analysis showing repression of NRF2 following NRF2 knockdown by SiRNA in PEO1 and SKOV3 cell lines. Cells were either
transfected with scrambled SiRNA (Sc) or transfected with 75 pmol of NRF2 SiRNA (Si). After 48 h, cells were either left untreated or treated
with 200 𝜇M tBHQ (T) for 4 h, before being processed for immunoblotting using relevant antibodies (Table 1). Ponceau stain of the same blot
was used as loading control. Bar chart shows NRF2 levels by quantifying immunoblot signal intensities obtained in (a) and normalised to the
value of untreated (UT) control and expressed as fold change. (b) Knockdown of NRF2 causes inhibition of its transcriptional antioxidant
program in both constitutive and tBHQ induced states. PEO1 and SKOV3 cells were transfected with either empty PGL3 basic vector or
1 𝜇g PGL3 basic vector with a cloned 8 x cis-antioxidant response elements (ARE) driving NRF2 dependent expression of luciferase gene.
Cotransfection with 0.2 𝜇g pRL-CMV plasmid was performed as an internal transfection control. Where required, cotransfection with either
scrambled RNA (Sc) or NRF2 SiRNA was performed using 20 pmol SiRNA. At 24 h after transfection, treatment with 200 𝜇M tBHQ was
performed where indicated for 4 h following which, cells were processed for dual luciferase reporter assay (Promega) to record luciferase
activity in multiplate reader (MODULUS, Promega). Data are the means with ±S.D. of triplicates normalised to the value of scrambled
SiRNA (Sc) and expressed as fold change with statistical significance determined by ONE WAY ANOVA followed by Tukey’s post hoc test.
∗ indicates significance of scramble versus treatment groups while # indicates significance of tBHQ versus tBHQ + NRF2 SiRNA groups
according to the scale symbolised by ∗ or #: 𝑝 < 0.05, ∗∗ or ##: 𝑝 < 0.01, and ∗ ∗ ∗ or ###: 𝑝 < 0.001.
coexpression of HER2/HER3 receptors, their ligand binding
dynamics, or changing preference for the dimerizing partner
[17, 21, 61, 74, 75] suggest that the anticancer effect of these
agents might be further optimized or be better predicted by
effectively limiting HER2/HER3 expression at the DNA level
or at least identifying a common regulatory centre of HER2
and HER3 transcription. Thus the identification of factors
that mediate or modulate the transcriptional expression of
HER2/HER3 will be paramount.
NRF2 has already been implicated in numerous reports
as a key contributor to resistance towards anticancer drugs.
However, most of these past studies have explored the role of
NRF2 in resistance against DNAdamaging agents [50, 51, 55].
The present study demonstrates that NRF2may regulate can-
cer cell proliferation, susceptibility, and resistance to targeted
therapy via transcriptional regulation of HER2/HER3. To
demonstrate the role of NRF2 in RTK signaling and thus in
determining responses to targeted therapies, we used HER2
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Figure 7: Continued.
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Figure 7: NRF2 knockdown causes downregulation of HER2 and HER3 levels, repression of pAKT, and sensitisation to targeted
immunotherapeutics. (a) Immunoblotting analysis showing inhibition of RTK signaling following depletion of NRF2 mRNA by SiRNA in
SKOV3 cell line. Exponentially growing cells were either transfected with scrambled SiRNA (Scrmbl) or transfected with 75 pmol of NRF2
SiRNA for either 24 or 48 h or 100 pmol of NRF2 SiRNA for 48 h and processed for immunoblotting using relevant antibodies (Table 1). 𝛽-
actin was used as a loading control. Bar chart shows protein levels by quantifying immunoblot signal intensities obtained and normalised to
the value of untreated (UT) control and expressed as fold change. (b) Immunofluorescent labelling of endogenous total HER2 or phospho-
AKT exhibits repression following NRF2 knockdown. Cells were transfected as in (a) and processed for immunocytochemistry. Relevant
primary antibodies were used to stain HER2 or phospho-AKT followed by Alexa Fluor conjugated secondary antibody (red fluorescence).
Nuclear reference was provided by costaining with 4󸀠,6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI). Images were captured with
Leica DMiRe2 electronicmicroscope at 100x objective while merging, colocalisation, and further analysis were performed by using integrated
features of Andor iQ Core software (ANDOR Technologies Ltd.). Scale bar indicates 10 𝜇m. (c and d) HER2 and HER3 downregulation
following NRF2 knockdown is caused by their transcriptional repression. Exponentially growing PEO1 cells (c) or SKOV3 cells (d) were
transfected with either empty PGL3 basic vector or 1𝜇g PGL3 basic vector with cloned 1.5 kb fragments of either HER2 (prHER2) or HER3
(prHER3) upstreampromoter regions driving the expression of luciferase gene. Cotransfectionwith 0.2 𝜇g pRL-CMVplasmidwas performed
as an internal transfection control. At 24 h after transfection, cells were either left untreated (UT) or treated with 200𝜇M tBHQ as indicated
for 4 h following which, cells were processed for dual luciferase reporter assay (Promega) to record luciferase activity in multiplate reader
(MODULUS, Promega). (d) The same was done for SKOV3 cell lines. (e) Knockdown of NRF2 through SiRNA sensitises cancer cell to RTK
inhibitors while parallel knockdown of KEAP1 partially relieves this sensitisation. Cells were transfected with scrambled SiRNA or SiRNA
targeting NRF2 either alone or with the inclusion of KEAP1 SiRNA. Following further 24 h incubation, cells were either left untreated or
treated with 25 𝜇g/mL of HER2 inhibitors Pertuzumab and Trastuzumab. Cytotoxicity assay was performed as in (a). In (c–e), data are the
means with ±S.D. of triplicates and expressed as fold change with statistical significance determined by ONE WAY ANOVA followed by
Tukey’s post hoc test (for c and d), or Student’s 𝑡-test (for e) according to the scale ∗: 𝑝 < 0.05, ∗∗: 𝑝 < 0.01, and ∗ ∗ ∗: 𝑝 < 0.001.
overexpressing (SKOV3) and low expressing (PEO1) ovarian
cancer cell lines [57] grown inHER receptor ligandHeregulin
and employed pharmacological and genetic activation or
inhibition of both NRF2-AR and HER2/HER3 signaling
pathways.
Firstly, pharmacological activation of NRF2 with tBHQ
enhanced ovarian cancer cell growth and protected cells
from cytotoxicity caused by combined HER2-targeted
immunotherapeutic agents, Pertuzumab and Trastuzumab.
This was also concomitant with the induction of HER2,
HER3, and pAKT proteins in oscillatory and dose-dependent
fashions, which is consistent with current emerging concepts
of transcriptional control and gene expression [70, 76–80].
Furthermore, NRF2 activation-dependent induction of the
receptors and their signaling pathway was governed and
executed by NRF2 at the transcriptional level of HER2 and
HER3 genes. Our results from both immunocytochemistry
and gene reporter assays of HER2 and HER3 expressions
were further supportive and reminiscent of recent reports
that revealed that induction of HER2 might repress HER3
expression while its inhibition led to transcriptional
induction of HER3 ([13, 14, 63], also see Figure 3(b)). It
is clear that tBHQ treatment led to induction of NRF2,
its associated antioxidant transcriptional program, and
transcriptional and signaling activation of HER2 and HER3
and that this tBHQ response was evidently dependent on
NRF2. Thus, NRF2 activation by tBHQ desensitised RTK
signaling pathway to inhibitory action of the HER2 targeting
immunotherapeutic agents Pertuzumab and Trastuzumab.
Next, to further investigate and confirm the involvement
of NRF2 in the elevation of HER2 and HER3, we took a
genetic approach to deplete NRF2 status and function using
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AGGGGTGAAATTTTTCTTTATCAAGGCTCAACTGTTTTCGAAGTCTTCAGGCTTGAAGTTCTGGAGAAA
ACAACTAGGCTCTCCGGGCGAGATCCCGAATACCAGTTTAAGGGATTTGAAATGCAAGGCCGTCTGGGA
CTCCACTGCCACGGATGGGCACCAGGCGGCGCCGGTCGGATCCGTCCCGGGACTAGCAGGGCTTTGGGC
AGCAACCCGCAGGGAGCCCGACCGCCTCTGGCCAGGTCCGGGCAGCTGGTGGGGGAGGTTCCAGAGGTC
CACGCCATTCGTGGACGCAGTCTCTAGTGTCCTCTCCGCGTCCCACTTCACTGCCCCATCCCCTTTCCT
GCGAGAGCCTGGACTTGGAAGGCACCTGGGAGGGTGTAAGCGCCTTGGTGTGTGCCCATCTGGGTCCCC
AGAAGAGCGGCGGGAACTGCGGCCGCCCGGACGGTGCGGCCAGACTCCAGTGTGGAAGGGGAGGCAGCT
GTTCTCCCAGGCGGCCGTGGGGGGCAGCAGAGGGGACGGCGACAGGTGCGGGAGCCCCTCCCGGGGTAG
AAGTGGAAAGGCGGGCTCCGGGGTCTGTTCCCAGGCTGGAAACCACCCCCGCCCCCCATCCAAATCCCC
GGGAGAGGCCCGGCCGGCGCCGGGTCTGGAGGAGGAAGCGGCCAGAGACAGTGCAATTTCACGCGGTCT
CTGTGGCTCGGGTTCCTGGGCTGGGTGGATGAATTATGGGGTTTCGAGTCTGGGAGAAACTGAGGTGGC
CTGGACGTGAGGCAAAAAACACCCTCCCCCTCAAAAACACACAGAGAGAAATATTCACATTCTGAGAGA
AAATCCACCAAGTGAACCAACCGGCTAGGGGAGTTGAGTGATTTGGTTAATGGGCGAGGCCAACTTTCA
GGGGGCAGGGCTTTGGAGAGCTTTCCACTCCCTCATTCATTACCCTTCCCTGGATCTGGGGGCTTTCGG
AATCTCGACCTCCCCTTGGCCTATCTCCTGCAGAAAAATTAGGGTGAGCCCCATCCTCGATCTGCTCCG
CCAAGTTGCGGGACCGCGGGGCGTGGCACGCTCGGGGCAGGCGGTCCGAGGCTCCGCAATCCCTACTCC
AGCCTCGCGCGGGAGGGGGCGCGGCCGTGACTCACCCCCTTCCCTCTGCGTTCCTCCCTCCCTCTCTCT
CTCTCTCTCACACACACACACCCCTCCCCTGCCATCCCTCCCCGGACTCCGGCTCCGGCTCCGATTGCA
ATTTGCAACCTCCGCTGCCGTCGCCGCAGCAGCCACCAATTCGCCAGCGGTTCAGGTGGCTCTTGCCTC
GATGTCCTAGCCTAGGGGCCCCCGGGCCGGACTTGGCTGGGCTCCCTTCACCCTCTGCGGAGTCATGAG
GGCGAACGACGCTCTGCAGGTGCTGGGCTTGCTTTTC
(b) Putative transcription factor binding sites found along HER3 promoter
Figure 8: In silico analysis of HER2 and HER3 promoter sequences. (a) 1.5 kb promoter region of 𝐻𝐸𝑅2 gene was fetched from database
(ensemble.org) and subjected to transcriptional factor binding prediction program (http://consite.genereg.net/) to predict for putative NRF2
binding sites as indicated. Line with arrowheads shows the 0.7 kb sequence of HER2 promoter [8], while regions enclosed in rectangles show
additional sequences included and cloned in the PGL3 luciferase reporter vector (Promega) because of carrying additionalNRF2 binding sites.
(b) The same analyses were performed for HER3 promoter. In (a) and (b), +1 indicate the transcriptional start site, sequences highlighted in
green showNRF2 binding sites as predicted by ConSite, and sequences in bold represent manual identification of putative NRF2 binding sites
based on ARE consensus sequence [9] while those highlighted in pink show overlapping NRF2 binding sites by the two methods mentioned
above.
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SiRNA. This approach increased cellular ROS, repressed
pNRF2 and HO-1 levels, and even disrupted the tBHQ
dependent induction of our ARE reporter system (Figures
5 and 6). In addition, NRF2 depletion by SiRNA caused
transcriptional repression of HER2 and HER3 leading to
lowered expression of HER2, HER3, and pAKT proteins.
As an alternative approach, we also cloned and overex-
pressed individually both NRF2 and KEAP1 genes in our
cancer cell lines and found these in either cytoprotection
or sensitisation to targeted therapies, respectively (data not
shown). Moreover, we illustrated that while knockdown of
NRF2 significantly sensitised ovarian cancer cells to targeted
immunotherapy, parallel knockdown of KEAP1 reversed this
sensitisation.These results support and confirmed our earlier
inferred regulatory role of NRF2 in the transcription of
HER2 and HER3 receptors and its association with alter-
ation of HER2 and HER3 proteins abundance. A recent
study has suggested a similar role for NRF2 in regulating
the expression of HER2 [73] but fell short of evidencing
direct transcriptional regulation as shown in this study. To
demonstrate transcriptional modulation of these receptors,
we generated and utilised luciferase reporter assays of their
proximal promoter sequencing spanning 1.5 kb regions. We
performed in silico analysis of these upstream regulatory
regions for the presence of NRF2 binding and ARE like
consensus sequences and found a number of such binding
sites (Figure 8). Moreover, a direct interaction of NRF2 and
HER2 in regulating the expression of NRF2 target genes,
including HO-1, via binding of the complex to the ARE of
the target genes has been reported [45] which adds credence
to our observed downregulation of HER2, HER3, and pAKT
as well as HO-1 and pNRF2 levels following our SiRNA-
mediated depletion of NRF2. However, further experiments
are necessary to confirm the role of NRF2 as a transcription
factor for HER receptors.
Thus we have shown that NRF2 regulates HER2 and
HER3 signaling pathway to modulate sensitivity to targeted
therapies.This demonstrates that NRF2 activation is not only
implicated in resistance to genotoxic agents as previously
shown [55] but can also lead to resistance to immunother-
apies involving Pertuzumab and Trastuzumab, whose actions
are very specific to HER2 receptors and unrelated to antioxi-
dant pathway until this study.
5. Conclusion
The effectiveness of current anticancer therapies that involve
DNA damaging and ROS producing agents is limited,
because of NRF2 dependent emergence of cellular resistance
to genotoxic agents. On the other hand, targeted anticancer
therapeutic agents, while being initially found to be promis-
ing, have their own limitations. These include predicting
their action and outcome owing to their tight dependence on
properties such as cell surface expression of receptors, their
dimerizing preferences, presence of ligands, and dynamics
of recycling/degradation. This study has found a novel node
of regulation between the AR and RTK signaling pathway.
As such, the central regulatory node that converges at tran-
scription factor NRF2 presents itself as a very attractive drug
target especially in both scenarios of resistance described
above. We have presented evidence at the gene expression,
protein induction, localisation, and cytotoxicity levels that
the two pathways are coregulated and together predict and
inform outcomes to targeted immunotherapies and that such
responses could be controlled bymodulating NRF2 function.
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